BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30988330)

  • 21. Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis.
    Su XJ; Zeng XT; Fang C; Liu TZ; Wang XH
    Oncotarget; 2017 May; 8(20):33953-33960. PubMed ID: 28430620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The causal effect of metabolic syndrome and its components on benign prostatic hyperplasia: A univariable and multivariable Mendelian randomization study.
    Lv K; Yang G; Wu Y; Xia X; Hao X; Pang A; Han D; Yuan Q; Song T
    Prostate; 2023 Oct; 83(14):1358-1364. PubMed ID: 37455410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen receptor CAG polymorphism and the risk of benign prostatic hyperplasia in a Brazilian population.
    Biolchi V; Silva Neto B; Koff W; Brum IS
    Int Braz J Urol; 2012; 38(3):373-9. PubMed ID: 22765868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men.
    Han Z; Zhang L; Zhu R; Luo L; Zhu M; Fan L; Wang G
    Medicine (Baltimore); 2017 Mar; 96(13):e6473. PubMed ID: 28353585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population.
    Qi J; Tian L; Chen Z; Wang L; Tao S; Gu X; Na R; Jiao Y; Kang J; Zheng S; Xu J; Sun J
    Prostate; 2013 Aug; 73(11):1182-90. PubMed ID: 23620269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leukocyte Telomere Length and the Risk of Prostate Cancer and Benign Prostatic Hyperplasia: Insights From UK Biobank and Mendelian Randomization Study.
    Lv K; Wu Y; Yang G; Hao X; Huang S; Song T; Yuan Q
    J Gerontol A Biol Sci Med Sci; 2024 Mar; 79(3):. PubMed ID: 38085929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
    Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
    DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
    Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
    Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
    [No Abstract]   [Full Text] [Related]  

  • 30. Kallikarein-related peptidase 3 common genetic variant and the risk of prostate cancer.
    Motamedi RK; Sarhangi N; Afshari M; Sattari M; Jamaldini SH; Samzadeh M; Mohsen Ziaei SA; Pourmand GR; Hasanzad M
    J Cell Biochem; 2019 Sep; 120(9):14822-14830. PubMed ID: 31017705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
    Gudmundsson J; Sigurdsson JK; Stefansdottir L; Agnarsson BA; Isaksson HJ; Stefansson OA; Gudjonsson SA; Gudbjartsson DF; Masson G; Frigge ML; Stacey SN; Sulem P; Halldorsson GH; Tragante V; Holm H; Eyjolfsson GI; Sigurdardottir O; Olafsson I; Jonsson T; Jonsson E; Barkardottir RB; Hilmarsson R; Asselbergs FW; Geirsson G; Thorsteinsdottir U; Rafnar T; Thorleifsson G; Stefansson K
    Nat Commun; 2018 Nov; 9(1):4568. PubMed ID: 30410027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of LTβR gene polymorphisms with prostate volume in benign prostatic hyperplasia in the Korean population.
    Lee SH; Kim SK; Yoo KH; Chung JH; Chang SG
    Genet Mol Res; 2015 Dec; 14(4):18607-15. PubMed ID: 26782510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between vitamin D receptor gene polymorphisms and genetic susceptibility to benign prostatic hyperplasia: A systematic review and meta-analysis.
    Ruan L
    Medicine (Baltimore); 2024 Mar; 103(9):e37361. PubMed ID: 38428858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review and meta-analysis of candidate gene association studies of benign prostate hyperplasia.
    Lin L; Li P; Liu X; Xie X; Liu L; Singh AK; Singh HN
    Syst Rev; 2022 Apr; 11(1):60. PubMed ID: 35382870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.
    White JA; Kaninjing ET; Adeniji KA; Jibrin P; Obafunwa JO; Ogo CN; Mohammed F; Popoola A; Fatiregun OA; Oluwole OP; Thorpe RJ; Karanam B; Elhussin I; Ambs S; Tang W; Davis M; Polak P; Campbell MJ; Brignole KR; Rotimi SO; Dean-Colomb W; Odedina FT; Yates C
    Prostate; 2024 Apr; 84(5):460-472. PubMed ID: 38192023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis.
    Luo J; Dunn T; Ewing C; Sauvageot J; Chen Y; Trent J; Isaacs W
    Prostate; 2002 May; 51(3):189-200. PubMed ID: 11967953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia.
    Tayeb MT; Clark C; Haites NE; Sharp L; Murray GI; McLeod HL
    Saudi Med J; 2004 Apr; 25(4):447-51. PubMed ID: 15083213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenetics of prostate cancer and benign hyperplasia--the potential use of an HLA-G variant as a tag SNP for prostate cancer risk.
    Zambra FM; Biolchi V; de Cerqueira CC; Brum IS; Castelli EC; Chies JA
    HLA; 2016 Feb; 87(2):79-88. PubMed ID: 26889902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia.
    Tsuchiya N; Wang L; Horikawa Y; Inoue T; Kakinuma H; Matsuura S; Sato K; Ogawa O; Kato T; Habuchi T
    Int J Oncol; 2005 Jan; 26(1):225-31. PubMed ID: 15586244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis.
    Middleton LW; Shen Z; Varma S; Pollack AS; Gong X; Zhu S; Zhu C; Foley JW; Vennam S; Sweeney RT; Tu K; Biscocho J; Eminaga O; Nolley R; Tibshirani R; Brooks JD; West RB; Pollack JR
    JCI Insight; 2019 May; 5(12):. PubMed ID: 31094703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.